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Abstract 18 
 Nasal colonization with methicillin-resistant Staphylococcus aureus is poorly described for 19 
surgeons, despite the increased exposure to nosocomial pathogens and at-risk patients. This study 20 
investigated the molecular epidemiology and antimicrobial resistance of 26 MRSA isolates 21 
cultured from the nares of an international cross-sectional study of 1,166 human and 60 veterinary 22 
surgeons. All isolates were subjected to agr-, spa- and MLST typing and the presence of 22 23 
virulence factors were screened for by PCR. Additionally, biofilm-forming ability, haemolytic 24 
activity, staphyloxanthin production and antibiotic resistance were determined. The genome of a 25 
rifampicin resistant MRSA was sequenced. Approximately half of the isolates belonged to well-26 
described clonal lineages, ST1, ST5, ST8, ST45 and ST59, that have been previously associated 27 
with severe infections and increased patient mortality. Two of the 3 veterinarian MRSA belonged 28 
to epidemic livestock-associated MRSA clonal lineages (ST398 and ST8) previously associated 29 
with high transmission potential between animals and humans. The isolates did not display any 30 
consistent virulence gene pattern, and 35% of the isolates carried at least one of: the Panton-31 
Valentine leukocidin lukFS-PV; the exfoliative toxin eta; or the toxic shock syndrome tst genes. 32 
Resistance to rifampicin was detected in one veterinarian isolate, and was found to be due to 3 33 
mutations in the rpoB gene. Surgeons occupy a critical position in the healthcare profession due to 34 
their close contact with patients.  In this study, surgeons were found to be colonized with MRSA 35 
at low rates that are similar to the general population, and the colonising strains were often 36 
common clonal lineages.  37 
 38 
Introduction 39 
Staphylococcus aureus colonizes between 26-35% of healthy humans, with the moist squamous 40 
epithelium of the anterior nares considered the primary reservoir (1-4). Due to its importance as a 41 
pathogen responsible for a wide range of difficult-to-treat infections, colonization with 42 
methicillin-resistant S. aureus (MRSA) has been investigated extensively in patients, but to a 43 
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lesser extent in their primary care-givers, including health care workers (HCWs) such as 44 
orthopaedic surgeons. Studies have consistently shown that average MRSA colonization rates are 45 
between 1-3% in the general population (5, 6), with increased rates shown for certain groups such 46 
as the elderly in assisted living facilities (6) or long-term in-patients (2), and those with immunity 47 
defects such as HIV, chronic granulomatous disease (CGD), Job’s syndrome, Chediak-Higashi 48 
syndrome, and Wiskott-Aldrich syndrome (7, 8).  49 
Recently, the MRSA colonization rate in an international cohort of human and veterinary 50 
orthopaedic surgeons was investigated (9). From a total cohort of 1,166 human surgeons, the 51 
MRSA colonization rate was 2% (23/1,166) and was 5% (3/60) amongst the veterinary surgeons 52 
(9). What remains undocumented within this study is the molecular epidemiology of these MRSA 53 
isolates. Previous studies have identified that distinct clonal lineages belonging to different 54 
sequence types (STs) or clonal complexes (CCs) have emerged and spread across the world (10-55 
12). For example, USA300 isolates (ST8) have been documented across the US and beyond, (11). 56 
Interestingly, livestock-associated (LA)-MRSA such as ST398 have been found on humans living 57 
and working on farms (13-15). It has also been shown that veterinary surgeons are at increased 58 
risk of carrying the same epidemic MRSA isolates as the animals (13-15). This clearly 59 
demonstrates the possibility of transmission between animal and human carrier and vice versa. 60 
We hypothesize that the MRSA nasal isolates collected from a cross-sectional study from human 61 
and veterinary surgeons will belong to well-known MRSA lineages. Therefore the aim of this 62 
study was to phenotypically and genotypically characterise the 23 MRSA nasal isolates from 63 
human surgeons as well as 3 MRSA isolates from veterinary surgeons, and determine the clonal 64 
relationship of these nasal isolates to known globally disseminated MRSA lineages. 65 
 66 
Materials and Methods 67 
Methicillin-resistant Staphylococcus aureus (MRSA) collection 68 
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MRSA isolates were obtained from a previously described study (9). Twenty-three MRSA isolates 69 
were recovered from the nares of 1,166 human orthopaedic surgeons sampled on an anonymous 70 
basis during an educational course in Switzerland in 2013. Furthermore, 3 additional MRSA 71 
isolates were collected from 60 veterinary orthopaedic surgeons not described in the previously 72 
study (9) but were included in the present study. The study was approved by the "Ethik-73 
Kommission der Bayerischen Landesärztekammer", Germany (Approval number 13090). Beside a 74 
nasal swab all participants gave information on basic demographic and professional questions 75 
such as location of place of work and birth (country and region). Bacterial isolation and 76 
identification was performed as described previously (9). After identification a single colony was 77 
taken and resuspended in 1 ml Tryptone Soy broth (TSB, Sigma Aldrich, Buchs, Switzerland) 78 
containing 20% vol/vol glycerol and stored at -80°C. Isolates were re-grown either on Tryptone 79 
Soy Agar (TSA, Sigma Aldrich, Buchs, Switzerland) plates or in TSB media for phenotypic 80 
characterization or for genomic DNA isolation. The 23 MRSA human orthopaedic surgeon 81 
isolates and their antimicrobial resistances were partially described by Morgenstern et al. 2016 (9). 82 
A more detailed profile of each individual isolate was analysed in this study.  83 
 84 
Phenotypic characterisation 85 
Antibiotic susceptibility testing 86 
Antibiotic susceptibility to 28 antibiotics (amikacin, ampicillin-sulbactam, cefotaxim, cefoxitin, 87 
cefuroxime, ciprofloxacin, clindamycin, daptomycin, erythromycin, fosfomycin, fusidic acid, 88 
gentamicin, levofloxacin, linezolid, mezlocillin, moxifloxacin, netilmicin, ofloxacin, oxacillin, 89 
penicillin, piperacillin, rifampicin, tetracycline, ticarcillin/clavulanate, tigecycline, tobramycin, 90 
trimethoprim-sulfamethoxazole and vancomycin) were determined using a Vitek2 machine 91 
(bioMérieux Vitek Inc., Hazelwood, MO, USA). Multiple antibiotic resistance was defined 92 
according to the definitions of the European Committee of Antimicrobial Susceptibility Testing 93 
(EUCAST). Oxacillin resistance was considered definitive for methicillin resistant status.  94 
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 95 
Cefoxitin disc diffusion test 96 
To confirm isolates as methicillin resistant, a cefoxitin disc diffusion test was performed at Synlab 97 
Suisse (Luzern, Switzerland) using a 30 µg disc. Zone sizes were measured and interpreted 98 
according to EUCAST interpretative criteria (http://www.eucast.org/clinical_breakpoints). 99 
 100 
Mupirocin disc diffusion test 101 
Resistance to mupirocin was tested on all isolates at Synlab Suisse (Luzern, Switzerland) by disc 102 
diffusion test using a 200 µg disc. Zone sizes were measured and interpreted according to 103 
EUCAST interpretative criteria (http://www.eucast.org/clinical_breakpoints). 104 
 105 
Staphyloxanthin production, haemolytic activity and biofilm production 106 
Staphyloxanthin production was tested as described previously (16) by two independent observers. 107 
S. aureus Newman and USA300 were included as positive controls for strong and S. aureus COL 108 
and UAMS-1 for weak staphyloxanthin production, respectively (16).  109 
Haemolytic activity of each MRSA isolate was assessed as described previously (16). S. aureus 110 
reference isolates USA300 and UAMS-1 were used as controls for strong and absent haemolysis 111 
activity, respectively (16). 112 
Biofilm formation was assayed as described previously (17, 18). Briefly, overnight cultures grown 113 
in Tryptic Soy Broth (TSB, Sigma Aldrich, Buchs, Switzerland) were suspended in fresh TSB 114 
containing 1% glucose, to approximately 1x10
6
 CFU/ml, correlating to an optical density of 115 
0.02±0.005 at 600nm as measured with a Multiskan Go microplate reader (Thermo Scientific, 116 
Zürich, Switzerland). A total of 200 µl of the bacterial suspension was incubated in flat-bottomed 117 
96-well tissue culture-treated polystyrene microtitre plates (Nuclon, Nunc A/S, Denmark) for 24 h 118 
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at 37 °C. Plates were rinsed with phosphate-buffered saline (PBS, Sigma-Aldrich, Buchs, 119 
Switzerland) and stained with 150 µl of Gram`s crystal violet solution (Sigma-Aldrich, Buchs, 120 
Switzerland). The dye bound to the attached cells was solubilized by addition of 150 µl of 95% 121 
ethanol. Optical density was measured as absorbance at 595 nm using the Multiskan Go 122 
microplate reader. All isolates were tested in triplicate in three independent experiments. Each 123 
microtitre plate also consisted of negative controls (wells without bacterial inoculation). The 124 
results were evaluated using the scale described by Stepanovic et al. (17). S. epidermidis reference 125 
strain RP12 (ATCC 35983) was used as a control for strong biofilm production. 126 
 127 
Genotypic characterisation  128 
DNA extraction 129 
Whole-cell (genomic) DNA, used as template for PCR amplification, was prepared from single 130 
colonies using the Wizard® 143 Genomic DNA purification kit (Promega, Dübendorf, 131 
Switzerland) according to the manufacturer`s protocol.  132 
 133 
PCR amplification 134 
Specific primers, corresponding genes and PCR reaction conditions are previously described by 135 
Post et al. (Post et al., 2014) and summarized in Table 1. PCR amplification was carried out in a 136 
BioRad MyCycler Thermocycler (BioRad, Reinach Switzerland) in a total volume of 12.5 μl 137 
containing 10X Green GoTaq® 151 Reaction buffer (Promega, Dübendorf, Switzerland), 5 mM 138 
dNTP Mix (Promega, Dübendorf, Switzerland), 50 pmol of each primer, 1 unit of Taq DNA 139 
polymerase recombinant (Invitrogen, Zug, Switzerland) and 10-50 ng template DNA.  140 
 141 
Accessory gene regulator (agr) typing 142 
agr polymorphisms were detected by PCR as described by von Eiff et al. and Post et al. (18, 19) 143 
with primers listed in Table 1. 144 
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 145 
Microbial surface components recognizing adhesive matrix molecules (MSCRAMM) detection  146 
Genes coding for MSCRAMMs were screened for by PCR with primers previously described (18) 147 
with primers listed in Table 1. 148 
 149 
Staphylococcal enterotoxins and other toxins 150 
Genes coding for staphylococcal enterotoxins (SEA-SEE), Panton-Valentine leukocidin (PVL) 151 
and toxic shock syndrome toxin (TSST) were detected by PCR using primers previously described 152 
(18) with primers listed in Table 1. 153 
 154 
Methicillin resistance gene 155 
The methicillin resistance gene mecA was detected using primers previously described (18) and 156 
listed in Table 1. 157 
 158 
Spa typing 159 
The polymorphic repeat region (region x) of the S. aureus protein A encoded by the spa gene was 160 
amplified as described previously (20). The spa-type for each isolate was determined as described 161 
by Harmsen and colleagues (21) using the online tool Ridom SpaServer 162 
(http://spaserver.ridom.de/) with primers listed in Table 1. 163 
 164 
Multi-Locus Sequence Typing (MLST) 165 
MLST was performed with published primers following the instructions on 166 
http://saureus.mlst.net/.  167 
 168 
DNA sequencing and sequence analysis 169 
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PCR products were purified for sequencing using the PureLinkTM Quick Gel Extraction and PCR 170 
Purification Combo Kit (Invitrogen, Zug, Switzerland) following the manufacturer`s protocol. 171 
Automated sequencing was performed at Microsynth AG, Balgach, Switzerland on an Applied 172 
Biosystems ABI3730xl Sequence Analyser 5.2 using the ABI Big Dye® 182 system V3.1.  173 
 174 
Whole genome sequencing of MRSA-3 175 
Genomic DNA of MRSA-3 isolate was extracted using a Qiagen QiAmp DNA mini kit (Qiagen, 176 
Hilden, Germany) following the manufacturer`s protocol using 1 µg/ml lysostaphin (Sigma-177 
Aldrich, Buchs, Switzerland and 2 µg/ml lysozyme (Sigma-Aldrich, Buchs, Switzerland) to lyse 178 
the bacteria. Sequencing was performed using an Illumina MiSeq benchtop sequencer (Illumina, 179 
San Diego, CA, USA), and the 100 bp short read paired-end data was assembled using the de novo 180 
assembly algorithm within Velvet software (version 1.2.08) (22). Resulting data was archived in 181 
the Staphylococcal Bacterial Isolate Genome Sequence database (BIGSdb) (23). The S. aureus 182 
MRSA252 reference genome (Genbank accession number BX571856.1) (24) was used as a basis 183 
for defining locus designations, and reference sequences. A ribosomal multilocus sequence typing 184 
(rMLST) approach was used to investigate the genetic relationship between MRSA-3 and 181 185 
published S. aureus isolates from the National Center for Biotechnology Information (NCBI). 186 
Orthologs for the 53 genes encoding the bacterial ribosome protein subunits (rps genes) were 187 
defined in all isolates by comparison to the finished genome of MRSA252. To estimate the 188 
genealogies for these alignments, ClonalFrame, a model-based approach to determining 189 
microevolution in bacteria was used (25). The consensus tree represents combined data from three 190 
independent runs with 75% consensus required for inference of relatedness. Recombination events 191 
were defined as sequences with a length of >50 bp with a probability of recombination ≥75% over 192 
the length, reaching 95% in at least one site.  193 
The presence of genes associated with the Staphylococcal Cassette Chromosome (SCC) mec 194 
complex (mecA, mecR, ccrA and ccrB), the S. aureus chromosomal orfX gene located to the right 195 
9 
 
of the SCCmec integration site, ACME (arginine catabolic mobile element) locus (speG, aliD and 196 
arcA) and the rifampicin resistance gene (rpoB) were investigated for MRSA-3 by BLAST (basic 197 
local alignment search tool) comparison to reference genome MRSA252 (23, 26, 27). These genes 198 
were considered as being present when a BLAST match with a >70% nucleotide sequence identity 199 
on ≥50% of sequence length was recorded. Where present, the genes where mapped onto the 200 
rMLST tree to examine the significance of association between the clustering on the tree and the 201 
presence of a specific gene. 202 
 203 
Statistical analysis 204 
The prevalence of MRSA and the corresponding 95% confidence interval (95% CI) were 205 
calculated using SAS software (Version 9.2; Cary, NC, USA). 206 
 207 
Results 208 
Phenotypic characterisation 209 
Antibiotic resistance profile  210 
The 26 MRSA isolates were collected from carriers coming from different regions of Africa 211 
(2/59), Asia (14/252), Central America (1/22), Europe (6/673) and South America (3/115) (Table 212 
2). The MRSA rate was 2% (23/1,166; 95% CI 1.3;2.9) for human surgeons and 5% (3/60; 95% 213 
CI 1.0;13.9) for veterinary surgeons. All MRSA isolates had cefoxitin zone diameters <22 mm, 214 
confirming their methicillin resistance status. The mecA gene was also detected by PCR in all 26 215 
MRSA isolates, which is in concordance with the cefoxitin disc diffusion test and the results 216 
provided by the oxacillin test by the Vitek2 system. The antibiotic susceptibility profile of all 217 
MRSA isolates is listed in Table 2. Fifty percent (13/26 isolates) of all isolates were resistant to 218 
erythromycin and clindamycin of which 6/13 isolates showed also resistance to the 4 quinolones 219 
ciprofloxacin, ofloxacin, levofloxacin and moxifloxacin. Furthermore, 30.8% (8/26 isolates) were 220 
resistant to the 4 aminoglycosides gentamicin, tobramycin, amikacin and netilmicin. Half of the 221 
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aminoglycoside resistant isolates (15.4%) showed also erythromycin and clindamycin resistance. 222 
All 26 MRSA isolates were susceptible to mupirocin, the only agent approved for de-223 
contamination of MRSA nasal carriage. 224 
  225 
Haemolytic activity, staphyloxanthin production and biofilm production 226 
Forty-two percent of isolates displayed the yellow-orange or yellow colony pigmentation 227 
indicative of staphyloxanthin production (Table 3) and 69% of isolates were haemolytic (Table 3). 228 
One isolate was a strong biofilm producer, and 21 isolates did not produce a biofilm under the 229 
described experimental conditions. The remaining 4 isolates produced an intermediate biofilm. 230 
 231 
Genotypic characterisation 232 
Accessory gene regulator (agr) typing 233 
Fifty-four percent of isolates belonged to agr type I, followed by 27% agr type II and 12% agr III 234 
(Table 3). Two isolates did not belong to any of the 4 agr types. 235 
 236 
Microbial surface components recognizing adhesive matrix molecules (MSCRAMM) detection  237 
The virulence genes hlgC/B (gamma-hemolysin), icaA (intercellular adhesion), eno (laminin 238 
binding protein), clfA/clfB (fibrinogen binding protein) and sdrC (beta-neurexin binding protein) 239 
were present in all isolates (Table 3). Ninety-six percent and 85% of isolates carried the sdrE 240 
(platelet aggregation) gene and sdrD (fibrinogen binding protein) gene, respectively, while 73%, 241 
62%, 39% and 39% of isolates possessed the fib (fibrinogen binding protein), ebpS (elastin 242 
binding protein), cna (collagen binding protein) and the fnbB (fibrinogen binding protein and 243 
elastin binding protein) genes, respectively (Table 3). The bbp (bone sialoprotein binding protein) 244 
gene was not detected in any of the MRSA isolates. 245 
 246 
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Staphylococcal enterotoxins and other toxins  247 
Two isolates carried the Panton-Valentine leukocidin (PVL) lukFS-PV gene and 4 isolates 248 
possessed the tst (toxic shock syndrome toxin, TSST) gene; all 6 isolates originating from Asia 249 
(Table 3). Half of the isolates carried one of the 5 genes coding for staphylococcal enterotoxins 250 
(SE) A, B, C, D and E. The eta gene (exfoliative toxin) gene was present in 3 isolates (Table 3). 251 
 252 
Correlation of biofilm, antimicrobial resistance and virulence genes 253 
Only 1 of the biofilm producers was found to be resistant to most antibiotics (Table 2). All 5 254 
isolates producing a biofilm showed also haemolytic activity whereas only 1 produced 255 
staphyloxanthin (Table 3). The 2 isolates carrying the Panton-Valentine leukocidin (PVL) lukFS-256 
PV gene produced both intermediate biofilm. The sdrD gene was present in all and the cna gene in 257 
4/5 of isolates producing a biofilm (Table 3). 258 
 259 
Spa-typing 260 
In total, 22 different spa-types and 1 novel sequence repeat (Sequence repeat: 11-19-12-21-10-34-261 
24-24-34-22-25; Kreiswirth ID: YHGFC2BQQBLO) were identified (Table 3). Only 3 isolates 262 
belonged to the same spa-type t688, one each from a European, African and Asian carrier (Table 263 
3). Two isolates belonged to t437 and were collected from Asia.  264 
 265 
Multi-locus sequence types (MLST)  266 
MLST Sequence Types (ST) were determined for all 26 isolates. Sixteen different ST types were 267 
identified (Table 3), with the main types being ST5 (n=4), ST8 (n=3) and ST59 (n=3). All isolates 268 
within ST5 belonged to agr type II, whilst all ST8 and ST59 isolates were agr type I (Table 3).  269 
 270 
Whole genome sequence analysis of isolate MRSA-3 271 
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MRSA-3 was isolated from a veterinary surgeon from South America and was submitted for 272 
whole genome sequencing as it had a wide range of antibiotic resistance and was the only isolate 273 
to be rifampicin resistant (Table 2). Spa-typing and MLST revealed that it belonged to the ST8-274 
t064 clonal lineage. The ClonalFrame phylogenetic tree based on 53 S. aureus rMLST genes in 275 
Figure 1, shows the evolutionary relationship between MRSA-3 and 181 published S. aureus 276 
genomes. MRSA-3 was in the same cluster as other ST8 isolates. Further, the ACME locus genes 277 
speG, aliD and arcA and the SCCmec complex genes, mecA, mecR, ccrA, ccrB and orfX were all 278 
present in MRSA-3. The phylogenetic relationship of MRSA-3 to the other MRSA genomes is 279 
shown for the mecA gene on the neighbour joining tree (Figure 2a; MRSA-3 indicated by black 280 
arrow and dark red filled square).  281 
The MRSA-3 isolate was resistant to rifampicin (MIC ≥32 mg/L). Sequence NCBI BLAST 282 
analysis against the reference sequence of rifampicin susceptible S. aureus strain ATCC 25923 283 
(GenBank accession number CP009361) (MIC, ≤0.5 mg/L) revealed 20 nucleotide changes in the 284 
3552 bp rpoB sequence. However, only 3 nucleotide changes at position 1411 (GGA AAC), 285 
1430 (GCT GAT) and 2210 (TTT TAT) resulted in amino acid changes 471 (DN; 286 
AspAsn), 477 (AD; Ala  Asp) and 737 (FY; Phe  Tyr), respectively (Figure 3). The 287 
changes in MRSA-3 were not observed in the other published S. aureus ST8 genomes (Figure 2b). 288 
 289 
Discussion 290 
In this study, 26 nasal MRSA isolates obtained from human and veterinary surgeons were 291 
phenotypically and genotypically characterised. These 26 MRSA isolates were collected from a 292 
large international cohort of 1,166 human and 60 veterinary surgeons from Africa, Asia, Central 293 
America, Europe and South America. As previously described, the MRSA colonization rate 294 
amongst the human surgeons was 2% (23/1,166; 95% CI 1.3;2.9) indicating a colonization rate 295 
equivalent to the general population and from HCWs (5, 6, 9, 28-30). The MRSA rate for the 296 
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veterinary surgeons was 5% (3/60; 95% CI 1.0;13.9) which lies also in the colonization rate 297 
reported for veterinary personnel (31). 298 
 299 
The most prevalent STs in this study were ST5 and ST8. The 4 ST5 isolates were collected (one 300 
each) from a European, an African, an Asian and from a Central American surgeon. The ST5 301 
lineage is associated with the successful global HA-MRSA New York/Japan clone (ST5, 302 
USA100) and the "paediatric" clone (ST5) both belonging to one of the major MRSA clonal 303 
complexes CC5 (12, 32). However, polyclonal genesis within this lineage has been shown (12, 32) 304 
and the only consistencies within the 4 ST5 isolates in this study were that they all belonged to agr 305 
type II, and were negative for the genes lukFS-PV, tst and eta.  306 
In total, 3 isolates (2 from Asian surgeons and 1 from a South American veterinary orthopaedic 307 
surgeon) belonged to the ST8 (USA300) clonal lineage. This lineage is mainly associated in the 308 
US as CA-MRSA responsible for the most frequent and severe skin and soft tissue infections in 309 
emergency departments (11, 33). The reason for this is believed to be due to higher virulence 310 
including the production of toxins (12). This is consistent with the expression of staphyloxanthin 311 
and haemolytic activity in all 3 ST8 isolates as well as the possession of the tst gene in the 2 Asian 312 
isolates and the eta gene in the South American isolate.  313 
In most cases, the described ST-spa-type combinations identified in this study have previously 314 
been associated with increased severity and patient mortality in hospital settings. For example the 315 
ST1-t386 lineage from 1 Asian surgeon belonged to CC1 and is mainly associated with USA400 316 
ORSA IV, a CA-MRSA in the USA that caused paediatric deaths in the Midwest of the United 317 
States (11). Furthermore, the 2 ST59-t437 isolates from Asian surgeons belonged to a well 318 
described CA-MRSA clonal lineage in Asia causing skin and soft tissue infections as well as 319 
sepsis and severe pneumonia (34, 35). A recent study has also identified ST59-t437 isolates in 320 
several European countries demonstrating that S. aureus lineages are not restricted to particular 321 
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geographical regions or specific host environments (36), although in our study all ST59 isolate 322 
were associated with Asian surgeons.  323 
The importance of antibiotic use in food production and the risks of emergence of multiply 324 
antibiotic resistance pathogens within the food chain has resulted in an increasing awareness of the 325 
risk of transmission of MRSA within the sector, including veterinary orthopaedic surgeons (13-326 
15). In our study, 3 veterinary orthopaedic surgeons were culture positive for MRSA (2 from 327 
Europe, 1 from South America). Two of them were colonized with LA-MRSA clonal lineages, i.e. 328 
lineages previously cultured directly from livestock. For example, 1 veterinary orthopaedic 329 
surgeon from Europe was colonized with MRSA ST398-t011, belonging to CC398. CC398 is the 330 
most predominant LA-MRSA clonal lineage reported across the world (13-15), and has been 331 
detected in a variety of domesticated animals (13-15). CC398 has often been reported to be 332 
transmitted from animals to humans (13-15) with most human CC398 infections being superficial 333 
skin and soft tissue infections (14). The second veterinary-associated MRSA (from a South 334 
American veterinary surgeon) was also carrying a known clonal lineage, ST8-t064  (37). 335 
Furthermore, this ST8-t064 (MRSA-3) isolate was multiply antibiotic resistant including 336 
resistance to rifampicin. Resistance to rifampicin is a significant challenge in the treatment of 337 
orthopaedic device related infection since rifampicin is the sole clinically available antibiotic with 338 
significant activity against staphylococcal biofilms (38, 39). Whole genome sequencing revealed 3 339 
SNPs in the rpoB sequence, which led to a change in the amino acid sequence at positions 471, 340 
477 and 737. The amino acid change at position 477 from Alanine to Aspartic acid has been 341 
shown to be responsible for high level resistance to rifampicin (40-42).  342 
Comparison of MRSA-3 SCCmec complex genes, (mecA, mecR, ccrA and ccrB) and orfX gene to 343 
the other ST8 S. aureus genomes from NCBI revealed a close evolutionary relationship. In 344 
contrast, the rpoB neighbour joining tree showed that the relationship between MRSA-3 and the 345 
other ST8 isolates is more diverse, indicating that it has a different evolutionary history. The 346 
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ACME locus genes: aliD, arcA and speG were present in the MRSA-3 indicative for most ST8 347 
(USA300) CA-MRSA (43) while the lukFS-PV gene encoding PVL was absent. 348 
The phenotypic evaluation of all MRSA isolates revealed that the isolates displayed a range of 349 
staphyloxanthin production, haemolytic activity and biofilm forming potential. Screening for the 350 
most prevalent MSCRAMMs demonstrated the presence of most of the tested virulence genes in 351 
the majority of the 26 MRSA isolates. For example, the surface protein clumping factor B (clfB) 352 
present in all 26 surgeons isolates has been shown to promote attachment of S. aureus to human 353 
squamous nasal epithelial cells by binding to keratin-10 (1). In total 34.6% of the nasal MRSA 354 
either carried the PVL lukFS-PV gene, responsible for increased severe disease and clinical 355 
symptoms, including necrotic lesions of the skin (10, 11), the eta gene coding for exfoliative toxin 356 
enhancing the transmission of MRSA through skin-skin contact, due to the destruction of the 357 
epidermal barrier (44) or the toxic shock syndrome tst gene. This highlights the highly virulent 358 
potential of these nasal colonizing MRSA isolates. 359 
 360 
Conclusion 361 
The findings of this study have shown that the MRSA isolates cultured from surgeons possessed 362 
genes for a wide range of virulence factors and toxins but also belonged to clonal lineages 363 
described for their high transmission potential and are associated with increased infection severity 364 
and mortality. This indicates not only that the surgeons are a potential risk in spreading these 365 
lineages in clinical and healthcare settings, but also that they themselves are exposed to the 366 
acquisition of such isolates.  367 
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Legends 506 
Figure 1. Population structure of MRSA-3 (indicated by a black arrow and a dark red filled 507 
square) and 181 published S. aureus isolates constructed from 53 rMLST genes and implemented 508 
in ClonalFrame. Isolates labelled according to ST complex: ST1 (turquoise); ST5 (pink); ST8 509 
(red); ST22 (light blue); ST30 (blue); ST45 (green); ST398 (orange); singletons (yellow). The 510 
scale (0.1) is in coalescent units and represents the number of substitutions per site.  511 
 512 
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Figure 2. Phylogenetic trees of MRSA-3 (indicated by a black arrow and a dark red filled square) 527 
and 181 published S. aureus genomes based on the presence of: (a) mecA and (b) rpoB. Isolates 528 
labelled according to ST complex: ST1 (turquoise); ST5 (pink); ST8 (red); ST22 (light blue); 529 
ST30 (blue); ST45 (green); ST398 (orange); singletons (yellow). The scale bar (0.001) is in 530 
coalescent units and represents the number of substitutions per site.  531 
 532 
 533 
  534 
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Figure 3. Amino acid alignment of the rpoB gene region (421-780) in the rifampicin resistant 535 
MRSA-3 and the rifampicin susceptible S. aureus ATCC 25923 (GenBank accession number 536 
CP009361). White letters on black indicate the 3 amino acid changes identified in MRSA-3. 537 
 538 
MRSA-3  IGLSRMERVVRERMSIQDTESITPQQLINIRPVIASIKEFFGSSQLSQFMNQANPLDELT   480 539 
ATCC 25923 IGLSRMERVVRERMSIQDTESITPQQLINIRPVIASIKEFFGSSQLSQFMDQANPLAELT  540 
 541 
MRSA-3  HKRRLSALGPGGLTRERAQMEVRDVHYSHYGRMCPIETPEGPNIGLINSLSSYARVNEFG   540 542 
ATCC 25923 HKRRLSALGPGGLTRERAQMEVRDVHYSHYGRMCPIETPEGPNIGLINSLSSYARVNEFG  543 
 544 
MRSA-3  FIETPYRKVDLDTHAITDQIDYLTADEEDSYVVAQANSKLDENGRFMDDEVVCRFRGNNT   600 545 
ATCC 25923 FIETPYRKVDLDTHAITDQIDYLTADEEDSYVVAQANSKLDENGRFMDDEVVCRFRGNNT  546 
 547 
MRSA-3  VMAKEKMDYMDVSPKQVVSAATACIPFLENDDSNRALMGANMQRQAVPLMNPEAPFVGTG   660 548 
ATCC 25923 VMAKEKMDYMDVSPKQVVSAATACIPFLENDDSNRALMGANMQRQAVPLMNPEAPFVGTG  549 
 550 
MRSA-3  MEHVAARDSGAAITAKHRGRVEHVESNEILVRRLVEENGVEHEGELDRYPLAKFKRSNSG   720 551 
ATCC 25923 MEHVAARDSGAAITAKHRGRVEHVESNEILVRRLVEENGVEHEGELDRYPLAKFKRSNSG  552 
 553 
MRSA-3  TCYNQRPIVAVGDVVEYNEILADGPSMELGEMALGRNVVVGFMTWDGYNYEDAVIMSERL 780               554 
ATCC 25923 TCYNQRPIVAVGDVVEFNEILADGPSMELGEMALGRNVVVGFMTWDGYNYEDAVIMSERL  555 
  556 
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Table 1. Primers used in the molecular identification of virulence factors in this study
1
 557 
Gene Primer 
name 
Sequence (5`- 3`) Product 
size  
(bp) 
Annealing 
temp  
(°C) 
spa-typing    
spa 1095F AGACGATCCTTCGGTGAGC  60 
 1517R GCTTTTGCAATGTCATTTACTG   
agr-typing    
agr agr1-4-1 ATGCACATGGTGCWCATGC   
 agr1-2 GTCACAAGTACTATAAGCTGCGAT 439 55 
 agr2-2 TATTACTAATTGAAAAGTGCCATAGC 572 55 
 agr3-2 GTAATGTAATAGCTTGTATAATAATACCCAG 321 55 
 agr4-2 CGATAATGCCGTAATACCCG 657 55 
MSCRAMMs    
cna CNA-1 GTCAAGCAGTTATTAACACCAGAC 423 55 
 CNA-2 AATCAGTAATTGCACTTTGTCCACTG   
eno ENO-1 ACGTGCAGCAGCTGACT  302 55 
 ENO-2 CAACAGCATYCTTCAGTACCTTC   
ebpS EBP-1 CATCCAGAACCAATCGAAGAC  186 55 
 EBP-2 CTTAACAGTTACATCATCATGTTTATCTTTG   
fnbB FNBB-1 GTAACAGCTAATGGTCGAATTGATACT  524 55 
 FNBB-2 CAAGTTCGATAGGAGTACTATGTTC   
fib FIB-1 CTACAACTACAATTGCCGTCAACAG  404 55 
 FIB-2 GCTCTTGTAAGACCATTTTCTTCAC   
clfA CLFA-1 ATTGGCGTGGCTTCAGTGCT 292 55 
 CLFA-2 CGTTTCTTCCGTAGTTGCATTTG   
clfB CLFB-1 ACATCAGTAATAGTAGGGGGCAAC 205 55 
 CLFB-2 TTCGCACTGTTTGTGTTTGCAC   
sdrC sdrC-F ACGACTATTAAACCAAGAAC 560 45 
 sdrC-R GTACTTGAAATAAGCGGTTG   
sdrD sdrD-F GGAAATAAAGTTGAAGTTTC 500 45 
 sdrD-R ACTTTGTCATCAACTGTAAT   
sdrE sdrE-F CAGTAAATGTGTCAAAAGA 767 45 
 sdrE-R TTGACTACCAGCTATATC   
bbp BBP-1 AACTACATCTAGTACTCAACAACAG 575 55 
 BBP-2 ATGTGCTTGAATAACACCATCATCT   
icaA icaA-F GATTATGTAATGTGCTTGGA 770 50 
 icaA-R ACTACTGCTGCGTTAATAAT   
Toxins    
PVL luk-PV-1 ATCATTAGGTAAAATGTCTGGACA 
TGATCCA 
433 55 
 luk-PV-2 GCATCAASTGTATTGGATAGCAAA AGC   
hlg hlg-1 GCCAATCCGTTATTAGAAAATGC 937 55 
 hlg-2 CCATAGACGTAGCAACGGAT   
sea GSEAR-1 GGTTATCAATGTGCGGGTGG 102 57 
 GSEAR-2 CGGCACTTTTTTCTCTTCGG   
seb GSEBR-1 GTATGGTGGTGTAACTGAGC 164 57 
 GSEBR-2 CCAAATAGTGACGAGTTAGG   
sec GSECR-1 AGATGAAGTAGTTGATGTGTATGG 451 57 
 GSECR-2 CACACTTTTAGAATCAACCG   
sed GSEDR-1 CCAATAATAGGAGAAAATAAAAG 278 57 
 GSEDR-2 ATTGGTATTTTTTTTCGTTC   
see GSEER-1 AGGTTTTTTCACAGGTCATCC 209 57 
 GSEER-2 CTTTTTTTTCTTCGGTCAATC   
eta GETAR-1 GCAGGTGTTGATTTAGCATT 93 57 
 GETAR-2 AGATGTCCCTATTTTTGCTG   
etb GETBR-1 ACAAGCAAAAGAATACAGCG 226 57 
 GETBR-2 GTTTTTGGCTGCTTCTCTTG   
tst GTSSTR-1 ACCCCTGTTCCCTTATCATC 326 57 
 GTSSTR-2 TTTTCAGTATTTGTAACGCC   
23 
 
Methicillin resistance    
mecA MECA P4 TCCAGATTACAACTTCACCAGG 162 53 
 MECA P7 CCACTTCATATCTTGTAACG   
1
Table was taken and modified from Post et al. (Post et al., 2014) 558 
 559 
  560 
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Table 2. Antibiotic resistance profiles of the MRSA isolates.  561 
Region MRSA 
No.
1
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Africa 11 S S S S R R R S S S S S S S S 
 24
4
 S S S S S S S S S S S S S S S 
Asia 7 S S S S S S S S S S S S S S S 
 19 R R R R S R R S S S S S S S S 
 22 S S S S S R R S S S S S S S S 
 8 R R R R S S S S R ND S R R S S 
 17
4
 S S S S S R R S R R R R S S S 
 26
4
 R R R R S R R S R R R R S S S 
 4 R R R R S S S S S S S S S S S 
 16 R R R R S S S S S S S S S S S 
 1 S S S S S R R S S S S S S S S 
 12 S S S S R R R S R ND S R S S S 
 6 R R R R R R R S R R R R S S S 
 23 S S S S S R R S R R R R S S S 
 18 S S S S S R R S S S S S S S S 
 25 S S S S R R R S S S S S S S S 
Central 
America 
5 S S S S S R R S R R R R S S S 
Europe 2 S S S S R S S S S S S S S S S 
 13* R R R R R S S S S S S S R S S 
 15 S S S S S S S S S S S S S S S 
 9* S S S S S S S R S S S S S S S 
 21 S S S S S S S S S S S S S S S 
 20
5
 S S S S S S S S S S S S S S S 
South 
America
3
 
3* R R R R R R R S R R R R R R S 
10
4
 S S S S S S S S S S S S S S S 
 14 S S S S S R S S S S S S S S S 
Total 
(n=26)  
8  8 8 8 7 13 13 1 8 6 6 8 3 1 0 
1
All isolates were resistant (R) to: Penicillin, Oxacillin, Piperacillin, Mezlocillin, Ampicillin-562 
Sulbactam, Cefotaxime, Cefuroxime, Ticarcclavulans, Cefoxitin and all isolates were susceptible 563 
(S) to: Tigecycline, Fosfomycin, Daptomycin, Vancomycin, Linezolid. ND stands for not 564 
determined.  565 
2
Trim/Sulf: Trimethoprim-Sulfamethoxazole. 566 
3
MRSA-3 isolate submitted for whole genome sequencing. 567 
4
Indicates intermediate biofilm production. 568 
5
Indicates strong biofilm production. 569 
*Indicates MRSA isolated from veterinary surgeons. 570 
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Table 3. Summary of the phenotypic and genotypic characterization of the MRSA isolates. 571 
Region Isolate 
No. 
MLST CC
1
 spa-
type 
agr-
type
2
 
HLG
3
 STX
4
 lukFS-
PV 
tst cna fnbB ebpS fib sdrD sea seb sec sed see eta 
Asia 1 ST1 1 t386 III - + - - + - + + + - - - - - - 
Africa 11 ST5 5 t688 II + - - - - - + + + - - - + - - 
Asia 12 ST5 5 t688 II + + - - - - + + + - - - + - - 
Central 
America 
5 ST5 5 t895 II - - - - - - + + + - - - - - - 
Europe 9* ST5 5 t1340 II + + - - - - + + - + - - - - - 
Asia 4 ST8 8 t1767 I + + - + - + - + + - - + - - - 
Asia 16 ST8 8 New
5
  I + + - + - + - + + - - + - - - 
South 
America 
3* ST8 8 t064 I + + - - - + - + + - + - - - + 
Asia 6 ST45 45 t14861  0 + - - - + - + - + - - - - - + 
Europe 15 ST45 45 t230 I - - - - + - + - + - - - - - - 
Asia 19 ST59 59 t437 I + - - - - - + + + - - - - - - 
Asia 25 ST59 59 t437 I + + - + - - - + - - + - - - - 
Asia 22 ST59 59 t441 I + + - + - - - + - - + - - - - 
Asia 8 ST72 8 t3092 I + - - - - - + + + - - - - + - 
Asia 18 ST72 8 t324 I + - - - - - + + + - - - - - - 
Africa 24
#
 ST88 88 t786 III + + - - - + - + + - + - - - - 
Asia 7 ST97 97 t267 I + + - - - + + + + - - - - - - 
South 
America 
10
#
 ST207 S t525 III + - - - + + + + + - - - - - - 
Asia 17
#
 ST217 S t852 I + - + - + - - - + - - - - - - 
Europe 13* ST398 398 t011 0 - - - - + + - - + - - - - - - 
Europe 20
$
 ST425 S t6292 II + - - - + - + + + - - - - - - 
Europe 21 ST508 S t1203 I - - - - + - + - - - - - - - - 
South 
America 
14 ST641 S t002 II - - - - - - + + + - - - - - - 
Europe 2 ST2112 S t688 II - + - - - - + + + - - - + - + 
Asia 26
#
 ST2124 S t7428 I + - + - + - - - + - - - + - - 
Asia 23 ST2124 S t9446 I - - - - + - - - + - - - + - - 
1 
CC: Clonal complex with S: S: singeltons.  572 
2
 agr-type 0: no PCR product for any of the 4 agr types was obtained. 573 
3 
HLG: Haemolytic activity, (+ /- indicates active / not active). 574 
4 
STX: Staphyloxanthin production (+ /- indicates production / no production). 575 
5 
Kreiswirth ID: YHGFC2BQQBLO. 576 
#
Indicates intermediate biofilm production. 577 
$
Indicates strong biofilm production. 578 
26 
 
NB: + / - indicates a positive / negative PCR amplification *indicates the veterinarian nasal MRSA isolates. The hlgC/B, icaA, eno, clfA/clfB and sdrC genes were 579 
present in all isolates. Ninety-six percent of isolates carried the sdrE gene. 580 
